Dr. Konety presents, Are Novel Biomarkers Ready For Primetime in Routine Detection of Prostate Cancer?
Dr. David Crawford invites Dr. Badrinath Konety to provide a counterpoint discussion on novel biomarkers and their use in detecting prostate cancer. Although, Dr. Konety agrees with the value of biomarkers and that they can be used in addition to PSA tests, he is not sure they are ready for prime time. Dr. Konety proposes key questions on novel biomarkers including their level improvement, are they causing our objectives to conflict with each other and their cost-effectiveness.
State of the Art Review of Bladder Cancer Biomarkers
Dr. Badrinath Konety is professor and chair at the University of Minnesota, where he holds the Dougherty Family Chair in Uro-Oncology and is Director of the Institute for Prostate and Urologic Cancers.
Konety is a fellow of the American College of Surgeons and the American Urologic Association. He also is secretary/treasurer of the Societe Internationale d’Urologie (US Section). He has published more than 120 peer reviewed articles, as well as a number of book chapters and review articles. He is on the editorial board of several journals and is a member of multiple guideline panels. He has been awarded a number of grants from the DOD, NCI, ACS and CDC. He is recognized as an expert on prostate and bladder cancer. He has given presentations on a wide range of urologic oncology topics nationally and internationally. He has been listed on the Best Doctors in America since 2009.
Not so long ago, routine surgery to remove the prostate gland required four to six weeks of recovery time. Now it isn’t uncommon for a man who has had a prostatectomy at the University of Minnesota's Institute for Prostate and Urologic Cancers (IPUC) to be doing yard work and his other usual activities just three weeks later.
When are "watchful waiting" and "active surveillance" good options for men with prostate cancer?